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Biomaterials for the Treatment
of Alzheimer’s Disease
  
Darya Hadavi and André A. Poot*
Department of Biomaterials Science and Technology, Institute for Biomedical Technology and Technical Medicine (MIRA), 
University of Twente, Enschede, Netherlands
Alzheimer’s disease (AD) as a progressive and fatal neurodegenerative disease rep-
resents a huge unmet need for treatment. The low efficacy of current treatment methods 
is not only due to low drug potency but also due to the presence of various obstacles 
in the delivery routes. One of the main barriers is the blood–brain barrier. The increasing 
prevalence of AD and the low efficacy of current therapies have increased the amount of 
research on unraveling of disease pathways and development of treatment strategies. 
One of the interesting areas for the latter subject is biomaterials and their applications. 
This interest originates from the fact that biomaterials are very useful for the delivery 
of therapeutic agents, such as drugs, proteins, and/or cells, in order to treat diseases 
and regenerate tissues. Recently, manufacturing of nano-sized delivery systems has 
increased the efficacy and delivery potential of biomaterials. In this article, we review 
the latest developments with regard to the use of biomaterials for the treatment of AD, 
including nanoparticles and liposomes for delivery of therapeutic compounds and scaf-
folds for cell delivery strategies.
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iNTRODUCTiON
Neurological diseases, such as frontotemporal dementia, stroke-induced vascular dementia, and 
Alzheimer’s disease (AD), are characterized by the impairment of memory and cognitive functions 
(Han et al., 2015). More than 80% of dementia cases are caused by AD, which is categorized as one 
of the most occurring neurodegenerative diseases in the world (Anand et al., 2014). Moreover, AD 
is considered as a slow pandemic disease. Whereas currently, 3 out of 1000 individuals worldwide 
are suffering from AD, this is expected to increase to 12 per 1000 by the year 2050 (Brookmeyer 
et al., 2007).
Alzheimer’s disease can be classified as familial AD or sporadic AD, while they share clinical 
and pathological features, including progressive cognitive impairment, plaque deposits in the brain, 
axonal transport defects, synapse loss, and selective neuronal death. Only 5% of the AD cases are of 
familial type, whereas 95% belong to sporadic AD (Kim and Tsai, 2009; Thal and Fandrich, 2015). 
Another classification system for AD is based on the age of emerging. Whereas 1–6% of the AD cases 
emerges in 30- to 60-year-old people, which is known as early-onset AD, late-onset AD occurs in 
people older than 60 years with 90% prevalence (Mullane and Williams, 2013).
Alzheimer’s disease is characterized clinically by progressive decline in mental and cognitive 
ability. The disease begins with impairment in the part of the brain, which is responsible for learn-
ing, memorizing, thinking, and planning. This mental decline negatively affects the patients’ work 
and social life because they have difficulties in expressing themselves and organizing their thoughts 
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(Alzheimer’s Association, 2012). As the disease progresses, more 
changes occur in the personality and behavior of the patients and 
they need extensive help with daily activities. Shrinkage of the 
brain over time results in more signs of AD, such as decline of 
thinking and reasoning skills, inability to respond to the environ-
ment or to control movement (Alzheimer’s Association, 2012).
Since Dr. Alois Alzheimer did observe the presence of amyloid 
plaques [extracellular deposits of amyloid-beta (Aβ) peptide] 
and intracellular hyperphosphorylated neurofibrillary tangles 
(NFTs) in the brain as pathological features, many hypotheses 
concerning causative factors for AD have emerged (Armstrong, 
2013; Kumar et al., 2015). Three main causes of AD have been 
proposed. It can be due to dysregulation of the cholinergic 
system, which is related to cognitive impairment of the patient. 
Alternatively, AD can be due to accumulation of NFTs or deposi-
tion of Aβ peptide in the brain (Anand et al., 2014). NFTs are 
paired helical filaments resulting from hyperphosphorylation of 
tau proteins. These proteins are mostly found in the axons, and 
their hyperphosphorylation is caused by internal cell dysregula-
tion. NFTs severely harm neurotransmitter transport and axonal 
integrity (Sun et al., 2003). The formation of Aβ peptides is the 
result of cleavage of amyloid precursor protein (APP). APP is a 
type I transmembrane protein, which is highly expressed in the 
central nervous system (CNS) and suggested to be responsible for 
synapse formation, neurogenesis, axonal transport, cell signaling, 
and plasticity. During two enzymatic steps by β-secretase and 
γ-secretase, Aβ peptides mainly consisting of 40 or 42 amino acids 
are liberated from APP, forming Aβ oligomers, Aβ polymers, and 
eventually Aβ plaques (Thinakaran and Koo, 2008). The presence 
of NFTs and Aβ plaques in the brain causes shrinkage pressure, 
which leads to nerve cell apoptosis. This cell death process starts 
from the memory and learning regions of the brain and then 
spreads to other regions via transfer among nerve cells that 
are along anatomical pathways (Gunawardena and Goldstein, 
2001; Brunholz et al., 2012). Currently, the pathophysiology of 
AD is subject to changes. Recent studies claim that Aβ peptide 
and phosphorylated tau proteins are the reflection of damage in 
neurons rather than being responsible for the disease (Hardy and 
Selkoe, 2002). It has been suggested that formation of NFTs is due 
to an adaptive strategy of cells to oxidative stress over the long 
term. Nevertheless, among all hallmarks of AD, Aβ deposition is 
the prevailing one for more than two decades and considered as 
an important causative factor of AD (Hardy and Selkoe, 2002).
It has been shown that Aβ oligomers are the primary struc-
tures leading to damage of normal functions of the brain (Gu 
et al., 2009; Orive et al., 2009). Based on studies on familial AD, 
mutations were only seen in APP and presenilin genes (PS1 
and PS2), and no mutations were reported for tau protein. This 
finding suggests that hyperphosphorylation and aggregation of 
tau protein in the form of NFTs result from the direct effect of 
Aβ peptides on tau protein (Ranka et al., 2002). The involvement 
of Aβ oligomers in synaptic impairment suggests that they have 
negative effects on postsynaptic structure and plasticity of the 
excitatory glutamatergic synapse (Shankar et al., 2008). As amy-
loid plaque formation is a rather late process (Orive et al., 2009), 
more insight in the formation of Aβ peptide is needed in order to 
get a comprehensive understanding of the etiology of this disease.
CURReNT TReATMeNT
The enormous financial and emotional burden of AD on patients, 
community and caregivers as well as increasing numbers of AD 
patients raise the essential need for an effective treatment. About 
a century after the discovery of this disease, only five drugs 
have been approved by the US Food and Drug Administration 
(FDA): acetylcholinesterase inhibitors rivastigmine (Exelon), 
galantamine (Razadyne and Reminyl), tacrine (Cognex), done-
pezil (Aricept), and NMDA receptor antagonist memantine 
(Namenda) (Musardo et al., 2013). These drugs are only able to 
target symptoms of AD and decrease the speed of progression 
of the disease. However, many patients do not respond to these 
drugs or the drugs have no profound effects on alteration of the 
process of AD (Han et al., 2015).
From 1998 to 2011, approximately 100 therapeutic compounds 
were tested in clinical trials for the treatment of AD, but they all 
failed. Among others, agents included inhibitors of γ-secretase 
and Aβ oligomer/fibril formation, as well as antibodies against Aβ 
(Mullane and Williams, 2013). This raised doubt on the causality 
of Aβ in the development of AD (Armstrong, 2014). Moreover, it 
was suggested that patients were treated too late, having irrevers-
ible brain damage 10–20 years after onset of the disease, explain-
ing the discrepancy with promising studies using animal models 
of AD (Mullane and Williams, 2013). Importantly, clinical failure 
of therapeutic agents was explained by low bioavailability in the 
CNS due to restriction by the blood–brain barrier (BBB) (Lauzon 
et al., 2015). In order to develop effective therapies for AD, much 
effort is needed to increase our knowledge of the involved disease 
pathways and to develop suitable drug delivery systems. With 
respect to the latter subject, the beneficial properties of biomateri-
als have been demonstrated, which are reviewed in this article for 
the treatment of AD.
As listed on the website http://clinicaltrials.gov, novel thera-
peutic compounds tested in clinical trials for the treatment of AD 
include the neurosteroid allopregnanolone (Irwin and Brinton, 
2014), the mast cell inhibitor masitinib (Folch et al., 2015), and 
the glucagon-like peptide-1 mimetic Exendin-4 (Hölscher, 2014). 
These agents are able to cross the BBB and thus may be effec-
tive without a biomaterial delivery system. Also, insulin is being 
tested in several trials (Hölscher, 2014). To prevent systemic 
administration, the insulin is delivered intranasally, which may 
benefit from a drug delivery system as shown below. Moreover, 
administration of mesenchymal stem cells is entering clinical 
trials for the treatment of AD (Hunsberger et al., 2016), which 
may also benefit from delivery strategies using biomaterials as 
reviewed below.
BiOMATeRiALS AND NANOTeCHNOLOGY
As defined by Williams (2009), a biomaterial is “a material 
intended to interface with biological systems to evaluate, treat, 
augment, or replace any tissue, organ, or function of the body.” 
Biomaterials are widely used in the fields of drug delivery and 
tissue engineering. One of the increasing applications of bioma-
terials is to overcome the inherent inability of the brain to protect, 
repair, and regenerate itself (Orive et al., 2009). One of the major 
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problems with respect to the treatment of  neurodegenerative 
diseases is related to drug delivery. Drug availability in the 
CNS is low due to the BBB, which restricts the accessibility of 
therapeutic compounds to the CNS. The BBB is formed by tight 
junctions between endothelial cells lining the cerebral capillaries. 
Compared to other parts of the circulation, the tight junctions of 
the BBB are more extensive and pinocytosis by the endothelial 
cells is limited (Ballabh et  al., 2004). The endothelial cells are 
surrounded by a basement membrane as well as pericytes and 
astrocytes, which provide structural and biochemical support to 
the BBB. The BBB protects the brain against pathogens, and only 
oxygen, carbon dioxide, and other lipophilic molecules with a 
molecular weight <600 g/mol can freely diffuse across the BBB. 
Other compounds, such as glucose, amino acids, and insulin, 
enter the brain via specific transporters or receptor-mediated 
endocytosis (Ballabh et al., 2004).
Because of the BBB, effective methods are needed for the deliv-
ery of therapeutic agents in the brain. Different approaches have 
been considered, such as conjugation of the active compounds to 
vectors, such as nanocarriers [liposomes, polymeric micelles, and 
lipid and polymeric nanoparticles (NPs)] with high affinity to the 
BBB, for instance, by interaction of the nanocarriers with various 
brain nutrient transport systems. An example of this is coating 
of NPs with thiamine, thereby targeting the particles to the BBB 
thiamine transporter (Lockman et al., 2003). Such vectors have the 
capacity of promoting active transport of drugs through the BBB 
(Popovic and Brundin, 2006; Beduneau et al., 2007). Moreover, 
implantation of drug-loaded biodegradable carriers, such as NPs 
and microparticles, enables delivery of a drug near the desired 
site of action. Recently, developed biomaterials can improve the 
targeted delivery of therapeutic compounds and cells to the brain, 
as reviewed below. These applications should lead to protection, 
repair, or regeneration of damaged CNS tissue (Orive et al., 2009).
Nanotechnology is one of the most important fields in biotech-
nology and has a major role in the development of novel thera-
peutic modalities with increased efficacy. In the nanotechnology 
field, materials are engineered with functional organization on 
the nano scale (1–1000 nm). These materials are used for inter-
action with and stimulation of biological systems (e.g., cells or 
tissues) at the molecular level to induce physiological responses. 
Nanotechnology provides a route to get desired responses more 
selectively with better timing and lower side effects in comparison 
with conventional pharmacological approaches (Modi et  al., 
2009). Here, we review recent advances in the applications of 
nano-sized biomaterials for the treatment of AD, mainly based 
on the use of NPs and liposomal nanocarriers. The biomaterial 
delivery systems described in this article are schematically shown 
in Figure 1. Information on the accompanying therapeutic agents 
is listed in Table 1.
Nanoparticles
Polymeric Nanoparticles
Polymeric NPs, especially biodegradable NPs ranging in size 
from 10 to 1000  nm, are categorized as a major type of drug 
delivery system for the treatment of AD. This is due to their low 
toxicity, tunable degradation rate, and high drug loading capac-
ity combined with their ability to cross the BBB and target the 
CNS (Wilson, 2009). Polymers include poly(lactic acid) (PLA), 
poly(glycolic acid) (PGA), poly(lactic-co-glycolic acid) (PLGA), 
poly(caprolactone) (PCL), chitosan, gelatin, and poly(butyl 
cyanoacrylate) (PBCA). Coating of these NPs with the surfactant 
polysorbate 80 enables them to cross the BBB by adsorption of 
apolipoprotein E from the blood, generating low-density lipo-
protein mimics, which are taken up by cells of the BBB through 
receptor-mediated endocytosis (Wilson, 2009). Additionally, 
these types of NPs can have manipulated surface properties, such 
as a hydrophilic poly(ethylene glycol) (PEG) layer, which protects 
the loaded drug against recognition by the immune system or 
degradation by enzymes (Locatelli and Franchini, 2012). The 
above characteristics led to consider them as promising vehicles 
for the treatment of AD.
Growth Factor-Loaded Polymeric Nanoparticles
The interaction of growth factors (GFs) with their receptors on 
cell surfaces leads to activation of different signaling pathways. 
Each of these pathways is responsible for a different cellular 
behavior, such as survival, proliferation, and differentiation. 
Administration of GFs, such as insulin-like growth factor (IGF), 
basic fibroblast growth factor (bFGF), and nerve growth factor 
(NGF), which are normally present in the brain, shows beneficial 
effects on the pathophysiology of AD in animal models (Lauzon 
et al., 2015). However, delivery of GFs to the brain is highly chal-
lenging due to the BBB, sensitivity of GFs to enzymatic degrada-
tion, clearance, and denaturation in the blood and the brain (Di 
Stefano et al., 2011).
Kurakhmaeva et al. (2009) prepared NGF-loaded PBCA NPs 
of 250 nm coated with polysorbate 80. Intravenous administra-
tion of the particles in a mouse model of scopolamine-induced 
amnesia significantly improved memory function of the animals. 
Treatment with NGF-loaded PBCA NPs without polysorbate 
80 coating also showed a positive effect, but less than with the 
surfactant.
Intranasal injection is a suitable administration route for NPs 
because of its large surface area, close distance to the brain, and 
high capillary density. By intranasal administration, particles are 
probably taken up by the olfactory epithelium and subsequently 
transported to the cerebrospinal fluid, thereby bypassing the BBB 
(Thorne et al., 2004). Zhang et al. (2014a) prepared PEG-PLGA 
NPs of 120  nm loaded with bFGF and coated with Solanum 
tuberosum lectin to target the nasal epithelium. Intranasal 
administration of the particles in a rat model of AD significantly 
improved spatial learning and memory capabilities of the ani-
mals. Intranasal NPs without lectin also showed positive effects, 
but less than with the lectin coating.
Nanoparticle Chelators
Abnormal metal ion homeostasis of the brain is also involved in 
the pathogenesis of AD and its characteristic Aβ neuropathology. 
Among other metal ions, enriched Fe, Zn, and Cu ions cause pre-
cipitation of Aβ and induce the formation of toxic Aβ oligomers 
(Adlard et al., 2008). This knowledge led to the development of a 
novel strategy to treat AD, based on metal-chelating compounds 
aiming to reverse or prevent Aβ aggregation. Moreover, these 
chelators can interfere with the role of redox metals in the 
FiGURe 1 | Schematic representation of AD/healthy brain tissue (top) and the biomaterial delivery systems described in this article (bottom).
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generation of free radicals and oxidative stress, which results in 
neurodegeneration.
In an in vitro model using cultured human cortical neurons, 
administration of polystyrene NPs of 240 nm covalently conju-
gated with a deferiprone chelator resulted in decreased cytotoxicity 
of Aβ peptide by prevention of Aβ aggregation (Liu et al., 2009). 
This suggests that the use of metal-chelating compounds could 
be a powerful approach for the treatment or prevention of AD. 
However, the application of such agents is limited due to toxic side 
effects and low bioavailability due to low penetration potential of 
TABLe 1 | Therapeutic agents mentioned in this article: current status, way of administration, and therapeutic effect.
Agent, section Status Administration effect
Rivastigmine, Current Treatment FDA approved Oral, plaster Selective pseudo-irreversible inhibition of 
acetylcholinesterase
Galantamine, Current Treatment FDA approved Oral Selective reversible inhibition of acetylcholinesterase
Tacrine, Current Treatment FDA approved Oral Non-selective reversible inhibition of 
acetylcholinesterase
Donepezil, Current Treatment FDA approved Oral Selective reversible inhibition of acetylcholinesterase
Memantine, Current Treatment FDA approved Oral Non-competitive inhibition of the N-methyl-d-aspartate 
receptor
Allopregnanolone, Current 
Treatment
Clinical trial Oral Increased expression of brain LXR and PXR receptors
Masitinib, Current Treatment Clinical trial Oral Inhibition of mast cells and tyrosine kinase fyn
Exendin-4, Current Treatment Clinical trial Oral Mimetic of glucagon-like peptide-1, acts as neuronal 
growth factor
Insulin, Current Treatment Clinical trial Intranasal Stimulation of cellular glucose uptake, growth factor-
like properties
Mesenchymal stem cell, Current 
Treatment
Clinical trial Intravenous or intracerebral injection of cell 
suspensions
Secretion of neurotrophic factors, differentiation to 
neuronal cells
IGF, Growth Factor-Loaded 
Polymeric Nanoparticles
Animal model Intravenous or intranasal injection of NPs Growth factor signaling
NGF, Growth Factor-Loaded 
Polymeric Nanoparticles
Animal model Intravenous or intranasal injection of NPs Growth factor signaling
bFGF, Growth Factor-Loaded 
Polymeric Nanoparticles
Animal model Intravenous or intranasal injection of NPs Growth factor signaling
Deferiprone, Nanoparticle Chelators In vitro model Addition of NPs Inhibition or reverse of Aβ aggregation by chelation of 
metal ions
d-penicillamine, Nanoparticle 
Chelators
In vitro model Addition of NPs Inhibition or reverse of Aβ aggregation by chelation of 
metal ions
Clioquinol, Nanoparticle Chelators Animal model, clinical trial Oral Inhibition or reverse of Aβ aggregation by chelation of 
metal ionsAnimal model Intravenous injection of NPs
Polyoxometalate/β-sheet breaker 
peptide, Gold Nanoparticles
In vitro model Addition of gold NPs Inhibition or reverse of Aβ aggregation by interfering 
with Aβ
Docosahexaenoic acid, Liposomes In vitro model Addition of liposomes Induction of non-amyloidogenic processing of APP
Curcumin, Liposomal Encapsulation 
of Natural Components
In vitro model Addition of liposomes Targeting of liposomes to Aβ fibrils
Quercetin, Liposomal Encapsulation 
of Natural Components
Animal model Oral, intranasal injection of liposomes Reduction of oxidative stress
Aβ peptides, Liposomal Vaccines Animal model Intraperitoneal injection of liposomes Immune response to Aβ peptides
Rivastigmine, Drug-Loaded 
Liposomes
Animal model Intraperitoneal or intranasal injection of 
liposomes
Increased acetylcholine esterase inhibition and longer 
time of action
BDNF, Neurotrophic Factor-Loaded 
Liposomes
Animal model Intravenous, -peritoneal, or -nasal injection 
of liposomes
Growth factor signaling
Donepezil, Microparticles Animal model Subcutaneous implantation of microparticles Selective reversible inhibition of acetylcholinesterase
Neural stem cell, Biomaterials for 
Cell Transplantation
Animal model Intracerebral injection of cell suspension and 
self-assembling peptide scaffold
Secretion of neurotrophic factors, differentiation to 
neuronal cells
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the chelators through the BBB. Both limitations can be improved 
by conjugation of the metal-chelating compounds to nanocarri-
ers. It was demonstrated that the above polystyrene-chelator NPs 
were properly taken up by brain tissue in vitro without change in 
metal-chelating capacity (Liu et al., 2006).
In an in  vitro study, the Cu (I) chelator d-penicillamine 
was covalently coupled by a disulfide bond to 70 nm lipid NPs 
made from hexadecanol and 1,2-dioleoyl-sn-glycero-3-phospho- 
ethanolamine-N-[3-(2-pyridyldithio)-propionate]. Metal-induced 
precipitation of Aβ was reversed by d-penicillamine released from 
the NPs by dithiothreitol (as a model for cellular glutathione), 
resulting in the formation of soluble deposits (Cui et al., 2005).
Another metal chelator is the quinoline derivative clioquinol 
(5-chloro-7-iodo-8-hydroxyquinoline) (CQ), which has affinity 
for Zn and Cu. Treatment of AD transgenic mice with CQ inhib-
ited metal-induced Aβ aggregation (Cherny et al., 2001). A pilot 
phase 2 clinical trial showed the ability of orally administered 
CQ to slow down cognitive decline (Ritchie et al., 2003). In order 
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to increase the bioavailability of CQ in the brain, the chelator 
was encapsulated in 40 nm PBCA NPs, which were coated with 
polysorbate 80. These CQ-NPs were found to efficiently cross 
the BBB in wild-type mice and thus have great potential for the 
treatment of AD (Roney et al., 2005).
Gold Nanoparticles
As described, destruction of Aβ fibrils and plaques is investigated 
as approach for the treatment of AD. This could also be achieved 
by the use of targeted gold NPs. Interaction of gold NPs with Aβ 
fibrils, and subsequent exposure to weak microwave fields, results 
in a local rise of temperature and dissolution of the fibrils. In vivo 
studies in mice demonstrated that treatment with gold NPs has 
the potential to slow down or stop the progression of AD, while 
these NPs cause no harmful effects in the brain (Lasagna-Reevesa 
et al., 2010). In a recent study, novel gold NPs conjugated with two 
compounds interfering with Aβ fibrils were used. These multi-
functional 22 nm gold NPs were able to decrease the cytotoxicity 
of Aβ fibrils and Aβ-mediated peroxidase activity in vitro (Gao 
et al., 2015). Thus, these results indicate that inorganic multifunc-
tional NPs have potential for the treatment of AD.
Liposomes
Liposomes are spherical vesicles that are composed of at least 
one relatively impermeable lipid bilayer surrounding an internal 
aqueous part. They usually consist of phospholipids such as 
phosphatidylcholine together with cholesterol. There is a consid-
erable interest in liposomes due to their capacity of delivering 
hydrophilic and hydrophobic molecules, biocompatibility, 
and non-toxicity. Hydrophilic and hydrophobic compounds 
are, respectively, carried in the aqueous and lipid parts of the 
liposomes. Although liposomes are a type of foreign material, 
when introduced into the biological system they do not cause 
negative biological responses, and, in general, liposomes are 
non-immunogenic, non-carcinogenic, non-thrombogenic, and 
biodegradable (Gregoriadis, 2008). Liposomes as nanocarriers 
with a large transport capacity have been used for drug delivery 
to the brain. This is because liposomes can encapsulate differ-
ent components, which are thereby properly protected against 
degradation by plasma enzymes and elimination by the reticu-
loendothelial system. Most importantly, liposomes are able to 
fuse with biological membranes, to be transported across cell 
membranes by endocytosis, and to penetrate through the BBB 
(Sinha et al., 2001). As discussed above for polymeric NPs, modi-
fication of the liposomal surface with PEG is a commonly used 
strategy to increase the half-life of liposomes in the circulation 
(Spuch and Navarro, 2011).
Gobbi et al. (2010) prepared liposomes with an average size of 
145 nm that were targeted to Aβ by incorporation of phosphatidic 
acid and cardiolipin. The high affinity of these liposomes in vitro 
to Aβ oligomers, but not to monomers, suggests that they may be 
useful for the targeted delivery of diagnostic and therapeutic com-
pounds in animal models of AD and clinical trials (Gobbi et al., 
2010). Canovi et al. (2011) prepared PEGylated nanoliposomes 
functionalized with anti-Aβ monoclonal antibodies. The results 
showed significant binding of the liposomes to Aβ monomers 
and fibrils in vitro, with a twofold higher affinity for the fibrils. 
Moreover, the liposomes bound to Aβ deposits in  post-mortem 
AD brain samples, indicating that this is a promising approach 
for the diagnosis and treatment of AD (Canovi et al., 2011). It 
should be noted that targeting of Aβ species in the blood may also 
be a valid strategy for lowering of Aβ levels in the brain, because 
blood and brain are in equilibrium through the BBB (Canovi 
et al., 2011).
Other potential applications of liposomes for the treatment of 
AD are based on their effects on cellular membranes. Addition 
of small (<200 nm) unilamellar phosphatidylcholine liposomes 
containing the omega-3 fatty acid, docosahexaenoic acid (DHA), 
to APP-overexpressing cells in vitro, resulted in an increase of cell 
membrane fluidity inducing the non-amyloidogenic processing 
of APP by α-secretase, leading to the formation of soluble APPα 
(sAPPα). Subsequently, sAPPα-containing cell supernatants were 
shown to inhibit the JNK stress signaling pathway and to activate 
the PI3K/Akt survival pathway in cultured neuronal cells, thereby 
preventing apoptotic cell death (Eckert et al., 2011). Thus, DHA-
containing liposomes can potentially be used for the treatment or 
prevention of AD, by enhancing the non-amyloidogenic process-
ing of APP.
Liposomal Encapsulation of Natural Components
Since there are no drugs to cure AD, current therapeutic strategies 
are based on inhibition of progress of the disease. Treatments are 
focused on targeting of metabolic dysfunction and the abnormal 
aggregation of tau proteins and Aβ peptides. (Citron, 2010). As 
discussed above, Aβ is initially released as monomer, which forms 
into oligomers, fibrils, and, eventually, a plaque. Although the 
oligomers are considered as the most toxic species, targeting of all 
Aβ forms is pursued for therapeutic and also diagnostic purposes 
(Spuch and Navarro, 2011).
For this approach, natural compounds could be used like cur-
cumin, which is a substance from turmeric plants that has anti-
inflammatory, antioxidant, and possibly anticancer properties, 
and might protect against AD. Liposomes with a size of 170 nm 
prepared from curcumin–phospholipid conjugates were shown 
to have a very high affinity to Aβ fibrils in  vitro, with a much 
lower affinity to Aβ monomers (Mourtas et al., 2011). Curcumin-
decorated liposomes only had a high affinity to Aβ fibrils, when 
the planar conformation of curcumin was maintained during 
preparation of the curcumin–phospholipid conjugates by means 
of click chemistry. It was concluded that these liposomes are 
promising vectors for the targeted delivery of therapeutic and 
diagnostic compounds in AD (Mourtas et al., 2011).
Quercetin, a flavonoid from fruits and vegetables, might also 
be useful for the treatment of AD. It has, among others, anticancer, 
anti-inflammatory, and antioxidant properties. As Aβ monomers 
are associated with oxidative stress-induced neurotoxicity, the 
antioxidant properties of quercetin may provide a protective or 
therapeutic effect in AD. Indeed, quercetin was shown to protect 
primary rat hippocampal neurons in culture from Aβ cytotoxicity, 
protein oxidation, lipid peroxidation, and apoptosis (Ansari et al., 
2009). Although oral administration of quercetin in the mouse 
improved learning and memory ability, this was hampered by the 
low intestinal absorption, high metabolization, and rapid elimi-
nation of quercetin (Lu et al., 2006). To overcome this, quercetin 
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was encapsulated in liposomes and administered via the nasal 
route. The results showed an antianxiety activity and a cognitive 
enhancing effect in the rat (Wattanathorn et al., 2007). Moreover, 
the same group showed that nasally administered quercetin-
containing liposomes were able to inhibit the degeneration of 
hippocampal neurons in a rat model of AD, partly via reduction 
of oxidative stress (Phachonpai et al., 2010).
Liposomal Vaccines
Liposomes have also been used for the preparation of vaccines 
against AD. Muhs et  al. (2007) incorporated a 15 amino acid 
sequence of Aβ peptide on the surface of liposomes, either by 
coupling of two fatty acid residues or two phospholipid/PEG 
spacers at both ends of the peptide. In the former case, the peptide 
adopted a β-sheet conformation, probably because of interactions 
of the peptide with the liposome surface. In the case of the PEG 
spacers, the peptide was present in a random coil conformation 
in the fluid phase surrounding the liposome. Intraperitoneal 
administrations in a transgenic mouse model of AD, only restored 
cognitive memory of the animals when a liposomal formulation 
containing the β-sheet form of the peptide was used. Moreover, 
in this case, a significant decrease in the amount of insoluble and 
soluble Aβ peptide in the brain of the mice was observed. These 
data show that AD is a “conformational” disease and that vaccina-
tion against β-sheet conformations of Aβ peptide has therapeutic 
potential.
Drug-Loaded Liposomes
Although the acetylcholinesterase inhibitor rivastigmine, which 
is FDA-approved for the treatment of AD, is well absorbed in the 
intestine, it has a half-life in blood of only 1.5 h. Therefore, the 
hydrophilic drug was encapsulated in phosphatidylcholine/cho-
lesterol liposomes, and administered orally and intraperitoneally 
in mice. As compared to administration of the free drug, the use 
of liposomes increased both the acetylcholinesterase inhibitor 
activity in the brain and the time of action (Mutlu et al., 2011).
Rivastigmine was also incorporated in soya lecithin/cholesterol 
liposomes and administered in rats via the intranasal route. As 
compared to intranasally and orally administered free drug, 
intranasal liposomes resulted in a higher concentration and longer 
half-life of rivastigmine in the brain (Arumugam et al., 2008).
Neurotrophic Factor-Loaded Liposomes
Neurotrophic factors, such as brain-derived neurotrophic factor 
(BDNF), exert beneficial effects on neuronal survival and syn-
aptic connectivity. Encapsulation in liposomes with appropriate 
surface properties, to increase the half-life of these factors in vivo 
and to facilitate targeting to the brain as described above, is con-
sidered as a viable strategy for the treatment of neurodegenerative 
diseases, such as AD (Spuch and Navarro, 2011).
Microparticles
Donepezil is an FDA-approved acetylcholine esterase inhibitor 
with high specificity for acetylcholine esterase in the CNS. It 
significantly improves cognition and functioning in daily life 
of mild- to moderate-AD patients, without clinical changes in 
vital organ functions during long-term treatment (>98  weeks) 
(Rogers and Friedhoff, 1998). Currently, donepezil is available as 
a daily tablet. However, gastrointestinal side effects of this drug 
and difficulties related to daily intake of the drug in AD patients 
with impaired memory limit its effective application. This may 
be overcome by the development of a long-term, non-gastroin-
testinal delivery system. PLGA was used for the preparation of 
donepezil-loaded microparticles with a size of 75  μm (Zhang 
et al., 2007). Subcutaneous implantation of the particles in rats 
resulted in steady-state plasma levels of donepezil for 4 weeks, 
after which release of the drug rapidly declined due to exhaustion 
of the particles. The microparticles were also implanted in rats 
with permanent ligation of the common carotid arteries, which 
results in loss of neurons and decrease of learning and memory 
capabilities. It was shown that subcutaneous implantation of the 
donepezil-loaded PLGA particles significantly improved learning 
and memory deficits during 30 days, to the same extent as daily 
oral administration of the free drug. This indicates that the cur-
rent treatment of AD with FDA-approved drugs may benefit from 
controlled release strategies (Zhang et al., 2007).
Biomaterials for Cell Transplantation
Current treatments of AD are focused on alleviation of the symp-
toms, rather than trying to inhibit or reverse the progress of the 
disease. As AD is characterized by neuronal cell death, a viable 
approach for treatment would be to prevent the loss of functional 
neurons or to replace damaged neurons. With respect to the lat-
ter aim, the use of neural stem cells (NSC) has been proposed. 
It was shown that transplantation of NSC resulted in improved 
cognition and synaptic conductivity in animal models of AD 
(Blurton-Jones et al., 2009; Zhang et al., 2014b).
Although only cells can be injected into the brain, the use of 
a scaffold has advantages in terms of cell adhesion and guidance, 
as well as protection from the hostile environment consisting of 
Aβ oligomers and aggregates. In this respect, scaffolds prepared 
from the peptide RADA16 are very interesting. RADA16 is a 
peptide consisting of four repeats of the sequence arginine– 
alanine–aspartic acid–alanine. It has alternating hydrophilic 
and hydrophobic residues and self-assembles in the presence of 
physiological concentrations of monovalent salt ions, such as Na+ 
and K+, into nanofibrous structures. A nanofiber consists of two 
stacked β-sheets with a hydrophobic core, a hydrophilic surface, 
a width of 3–8  nm, and a height of around 1.5  nm (Holmes 
et al., 2000; Cormier et al., 2013). RADA16 scaffolds were shown 
to support neurite outgrowth and synapse formation in  vitro 
(Holmes et al., 2000).
To increase the cell-supportive properties of these and other 
scaffolds, the peptide sequence YIGSR from the basement mem-
brane protein laminin was used. When grafted on the surface of 
poly(ethylene-co-vinyl alcohol) membranes, YIGSR moieties 
increased the migration, differentiation, and synaptic activity of 
NSC in vitro (Li et al., 2013).
The C-terminus of the RADA16 peptide was extended with 
the YIGSR sequence, which did not interfere with self-assembly. 
As shown by Cui et  al. (2016), these YIGSR-functionalized 
scaffolds promoted the neuronal differentiation of NSC and 
protected the cells against apoptosis by Aβ treatment in vitro, as 
compared to RADA16 control scaffolds. Moreover, hippocampal 
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transplantation of NSC with RADA16-YIGSR scaffolds improved 
spatial learning and memory in a rat model of AD. This was 
accompanied by increased neuronal survival and differentiation, 
less apoptosis, recovery of synaptic function, and increased neu-
rotrophin levels (Cui et al., 2016). These results indicate that the 
use of NSC together with biomaterials is a promising approach 
for the clinical treatment of AD.
Time Course for Delivery of Therapeutic 
Agents and Selection of Biomaterials
In general, a degradable biomaterial is used for the delivery of 
therapeutic agents. Release of the active compound, which is dis-
persed in the biomaterial phase, is determined by degradation of 
the material, see the bFGF-loaded PLGA NPs in Section “Growth 
Factor-Loaded Polymeric Nanoparticles” (Zhang et  al., 2014a). 
Thus, the degradation rate of the biomaterial must be fine-tuned 
to obtain the desired release profile of the therapeutic agent. This 
can be done by copolymerization. Both PLA and PGA have a 
relatively long degradation time (months), but PLGA degrades 
much faster (days–weeks). This is because PLA and PGA are 
crystalline materials, and PLGA is amorphous (Yang et al., 2001). 
The bFGF-loaded PLGA NPs (lactic acid:glycolic acid = 50:50) 
were daily administered in rats for 17 days via the nasal route, 
and peak concentrations of bFGF in the brain were reached 4 h 
after each administration (Zhang et al., 2014a). The degradation 
time of PLGA can be fine-tuned by varying the ratio of lactic 
acid:glycolic acid. The donepezil-loaded PLGA microparticles in 
Section “Microparticles” had a lactic acid:glycolic acid ratio of 
75:25. These particles degraded completely within 30 days after 
subcutaneous implantation in the rat (Zhang et al., 2007).
Likewise, PBCA is a suitable polymer for the delivery of 
therapeutic agents, see the NGF-loaded PBCA NPs in Section 
“Growth Factor-Loaded Polymeric Nanoparticles” and the 
CQ-loaded NPs in Section “Nanoparticle Chelators.” PBCA 
shows relatively fast intracellular degradation (T1/2 =  3  days). 
If desired, the degradation time of this kind of particles can be 
increased by copolymerization of butyl cyanoacrylate with octyl 
cyanoacrylate (Sulheim et al., 2016). Both NGF- and CQ-loaded 
PBCA NPs were coated with polysorbate 80 and administered by 
single intravenous injection in mice. This resulted in maximum 
concentrations in the brain 1 h after administration (Roney et al., 
2005; Kurakhmaeva et al., 2009).
Also, lipids are used for drug delivery, e.g., the solid lipid NPs 
in Section “Nanoparticle Chelators” conjugated with the Cu (I) 
chelator d-penicillamine. As shown in vitro, the chelator, which 
was covalently coupled to the particles via a disulfide bond, was 
only able to dissolve Aβ deposits after release from the particles. 
For this, dithiothreitol was used as a model for glutathione. Thus, 
although these particles are biodegradable, delivery of the active 
compound does not depend on degradation of the carrier (Cui 
et al., 2005).
Lipids are mostly used for controlled release in the form 
of liposomes, e.g., the unilamellar DHA-containing phos-
phatidylcholine liposomes in Section “Liposomes.” As shown 
in vitro, the cell membrane fluidity increased upon fusion with 
these liposomes (Eckert et  al., 2011). The curcumin-decorated 
liposomes in Section “Liposomal Encapsulation of Natural 
Components” were prepared from phospholipids, cholesterol, 
and phospholipid–curcumin conjugates, and were shown to 
be stable in  vitro for at least 24  h at 37°C in serum solutions 
(Mourtas et  al., 2011). The quercetin-loaded liposomes in 
Section “Liposomal Encapsulation of Natural Components” were 
prepared from phosphatidylcholine and cholesterol and admin-
istered intranasally once daily for 4  weeks in the rat. Already 
after the first dose, a cognitive enhancing effect was measured, 
which further increased until the end of the study (Wattanathorn 
et al., 2007). The same type of liposomes was used to encapsulate 
rivastigmine (see Drug-Loaded Liposomes). As shown in vitro, 
the stability of these liposomes significantly increased by incor-
poration of sodium taurocholate in the phospholipid double 
layer. Intraperitoneal administration of these liposomes in mice 
resulted in a fivefold higher inhibition of acetylcholinesterase in 
the brain during the next 24 h, as compared to rivastigmine alone 
(Mutlu et al., 2011). For the liposomal vaccines (see Liposomal 
Vaccines), standard liposomes were used to present Aβ sequences 
with specific conformations to the immune system. Six intra-
peritoneal injections of the vaccine were given, with intervals of 
2 weeks. The highest antibody titer (IgG) in blood was measured 
after the third inoculation in the case of Aβ peptide with a β-sheet 
conformation (Muhs et al., 2007). The liposomes can be expected 
to degrade within a few days after administration.
The scaffolds for transplantation of NSC in the brain were 
based on peptides that self-assemble into nanofibrous structures 
(see Biomaterials for Cell Transplantation). To prevent rapid 
degradation, the N- and C-termini of the peptides were acety-
lated and amidated, respectively. The nanofibers were stable for 
at least 2 weeks in cell culture. Learning and memory tests in a rat 
model of AD were carried out 4 weeks after injection of NSC and 
self-assembling peptides in the hippocampus (Cui et al., 2016). 
No data were provided about degradation of the scaffolds in vivo.
Sometimes, non-degradable polymers are used for drug 
delivery; see the polystyrene NPs conjugated with a deferiprone 
chelator in Section “Nanoparticle Chelators.” The chelator was 
covalently coupled to the particles, which were subsequently 
added to cultured neurons and brain tissue in vitro (Liu et  al., 
2006, 2009). Although the chelator was active after coupling, this 
raises questions about the fate of the non-degradable polystyrene 
NPs upon administration in vivo. The same holds for the gold NPs 
in Section “Gold Nanoparticles,” conjugated with compounds 
interfering with Aβ fibrils (Gao et al., 2015).
CONCLUSiON
Although many in vitro and preclinical studies have been pub-
lished aiming to inhibit or reverse the progress of AD, current 
clinical treatments are still based on fighting the symptoms of the 
disease. Either approved or in the experimental phase, however, 
all treatment strategies may benefit from the use of biomaterials. 
These are mostly in the form of nano- or micro-sized particles 
that can protect the therapeutic payload after administration. 
Moreover, the biomaterial particles can facilitate transport of 
the therapeutic compounds across the BBB and target them to 
pathological sites in the brain. In addition to drugs, the active 
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components can also be cells for regeneration of brain tissue. In 
this case, a biomaterial scaffold is used to guide and protect the 
cells. It is concluded that there is an increasingly important role 
for biomaterials in the treatment of AD.
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